Catherine London, who has more than two decades of experience in the pharma and healthcare sectors, has joined biOasis Technologies as executive VP-corporate affairs and IR. She reports to CEO Mark Day.
|
|
Catherine LondonMost recently, London did a two-year stint as corporate communications chief at Purdue Pharma, maker of Oxycontin.
Earlier, she held corporate and product PR positions at Alexion Pharmaceuticals and Boehringer Ingelheim and worked at communications firms Chandler Chicco and Ruder Finn.
At biOasis, London assumes a newly created post in charge of external communications, visibility, brand-building and financial communications.
CEO Day praised London as a “forward-thinking communications leader and collaborative relationship builder.”
biOasis, which is based in Vancouver, has developed treatments for neurological diseases such as brain cancers, neurodegenerative and metabolic diseases.
Even as technology changes the rules of engagement, digital health brands still control the most powerful tool they have—their story.
Havilah Clarke, head of marketing and communications at the Huntsman Mental Health Foundation and Institute, has joined Purposeful Advisors as a managing director.
How purpose-driven communications strengthens reputation, rallies stakeholders and builds value during economically turbulent times.
Why healthcare must prioritize more strategic communications integration.
